Initial Clinical Experience of RP5063 Following Single Doses in Normal Healthy Volunteers and Multiple Doses in Patients with Stable Schizophrenia

Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder

(2017) Marc Cantillon et al.   SCHIZOPHRENIA RESEARCH

A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia

(2015) Herbert Y. Meltzer et al.   JOURNAL OF CLINICAL PSYCHIATRY

Side effects of atypical antipsychotics: a brief overview

(2015) ALP ÜÇOK et al.   World Psychiatry

Worsened hypertension control induced by aripiprazole

(2013) Norio Yasui-Furukori et al.   Neuropsychiatric Disease and Treatment

Cognition and the five-factor model of the Positive and Negative Syndrome Scale in schizophrenia

(2012) Roberto Rodriguez-Jimenez et al.   SCHIZOPHRENIA RESEARCH

Schizophrenia

(2009) Jim van Os et al.   LANCET